Liver-specific expression of the agouti gene in transgenic mice promotes liver carcinogenesis in the absence of obesity and diabetes

Molecular Cancer

Volumn 3, Issue , 2004, Pages

  Kuklin, Alexander I ^a,c   Mynatt, Randall L ^a,d   Klebig, Mitchell L ^a,e   Kiefer, Laura L ^b,f   Wilkison, William O ^b   Woychik, Richard P ^a,g   Michaud, Edward J ^a  

^a OAK RIDGE NATIONAL LABORATORY   (United States)

^b GLAXOSMITHKLINE   (United States)

^c TRANSGENOMIC INC   (United States)

^d PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^e UNIVERSITY OF TENNESSEE   (United States)

^f Clinical Data Inc   (United States)

^g JACKSON LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGOUTI PROTEIN; ALBUMIN; ALPHA INTERMEDIN; CARCINOGEN; DIETHYLNITROSAMINE; GLUCOSE; INSULIN; ALBUMINOID; COMPLEMENTARY DNA; HYBRID PROTEIN; NONAGOUTI PROTEIN, MOUSE; SIGNAL PEPTIDE;

AGE; ANIMAL EUTHANASIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIABETES MELLITUS; GENE CONTROL; GENE EXPRESSION; GENETIC LINE; GLUCOSE BLOOD LEVEL; HORMONE BINDING; INSULIN BLOOD LEVEL; LIVER CARCINOGENESIS; LIVER LEVEL; LIVER TUMOR; LIVER WEIGHT; MOUSE; NONHUMAN; NORTHERN BLOTTING; OBESITY; PROMOTER REGION; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; QUANTITATIVE ANALYSIS; REGULATORY MECHANISM; SYNDROME; TRANSGENIC MOUSE; TUMOR PROMOTION; ANIMAL; ANTIBODY SPECIFICITY; BIOSYNTHESIS; BLOOD; CHEMICALLY INDUCED DISORDER; CHEMISTRY; DRUG EFFECT; GENETICS; LIVER; MALE; METABOLISM; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY;

AGOUTI; MAMMALIA; MUS MUSCULUS;

AGOUTI SIGNALING PROTEIN; ALBUMINS; ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; CARCINOGENS; DIABETES MELLITUS; DIETHYLNITROSAMINE; DNA, COMPLEMENTARY; INSULIN; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER; LIVER NEOPLASMS; MALE; MICE; MICE, NUDE; MICE, TRANSGENIC; OBESITY; ORGAN SPECIFICITY; PROMOTER REGIONS, GENETIC; RECOMBINANT FUSION PROTEINS;

EID: 13644263660     PISSN: 14764598     EISSN: None     Source Type: Journal    
DOI: 10.1186/1476-4598-3-17     Document Type: Article

References (68)

1. Silvers WK: The agouti and extension series of alleles, umbrous, and sable. In The Coat Colors of Mice: A Model for Mammalian Gene Action and Interaction New York: Springer-Verlag; 1979:6-44.
2. Bultman SJ, Michaud EJ, Woychik RP: Molecular characterization of the mouse agouti locus. Cell 1992, 71: 195-1204.
3. Miller MW, Duhl DMJ, Vrieling H, Cordes SP, Ollmann MM, Winkes BM, Barsh GS: Cloning of the mouse agouti gene predicts a secreted protein ubiquitously expressed in mice carrying the lethal yellow mutation. Genes Dev 1993, 7:454-467.
4. Matsunaga N, Virador V, Santis C, Vieira WD, Furumura M, Matsunaga J, Kobayashi N, Hearing VJ: In situ localization of agouti signal protein in murine skin using immunohistochemistry with an ASP-specific antibody. Biochem Biophys Res Commun 2000, 270: 176-182.
5. Lu D, Willard D, Patel IR, Kadwell S, Overton L, Kost T, Luther M, Chen W, Woychik RP, Wilkison WO, Cone RD: Agouti protein is an antagonist of the melanocyte-stimulating-hormone receptor. Nature 1994, 371:799-802.
6. Blanchard SG, Harris CO, Ittoop OR, Nichols JS, Parks DJ, Truesdale AT, Wilkison WO: Agouti antagonism of melanocortin binding and action in the B16F10 murine melanoma cell line. Biochemistry 1995, 34:10406-10411.
7. Siegrist W, Drozdz R, Cotti R, Willard DH, Wilkison WO, Eberle AN: Interactions of alpha-melanotropin and agouti on B16 melanoma cells: evidence for inverse agonism of agouti. J Recept Signal Transduct Res 1997, 17:75-98.
8. Ollmann MM, Lamoreux ML, Wilson BD, Barsh GS: Interaction of Agouti protein with the melanocortin 1 receptor in vitro and in vivo. Genes Dev 1998, 12:316-330.
9. Eberle AN, Bodi J, Orosz G, Suli-Vargha H, Jaggin V, Zumsteg U: Antagonist and agonist activities of the mouse agouti protein fragment (91-131) at the melanocortin-1 receptor. J Recept Signal Transduct Res 2001, 21:25-45.
10. Abdel-Malek ZA, Scott MC, Furumura M, Lamoreux ML, Ollmann M, Barsh GS, Hearing VJ: The melanocortin 1 receptor is the principle mediator of the effects of agouti signaling protein on mammalian melanocytes. J Cell Sci 2001, 114:1019-1024.
11. Hustad CM, Perry WL, Siracusa LD, Rasberry C, Cobb L, Cattanach BM, Kovatch R, Copeland NG, Jenkins NA: Molecular genetic characterization of six recessive viable alleles of the mouse agouti locus. Genetics 1995, 140:255-265.
12. Miltenberger RJ, Wakamatsu K, Ito S, Woychik RP, Russell LB, Michaud EJ: Molecular and phenotypic analysis of 25 recessive, homozygous-viable alleles at the mouse agouti locus. Genetics 2002, 160:659-674.
13. vy/a) mice. The yellow mouse syndrome. J Hered 1986, 77:151-158.
14. Wolff GL: Body weight and cancer. Am J Clin Nutr 1987, 45:168-180.
15. Jackson IJ: Colour-coded switches. Nature 1993, 362:587-588.
16. vy/- mice: ectopic expression of the agouti gene. FASEB J 1994, 8:479-488.
17. Perry WL, Copeland NG, Jenkins NA: The molecular basis for dominant yellow agouti coat color mutations. Bioessays 1994, 16:705-707.
18. Manne J, Argeson AC, Siracusa LD: Mechanisms for the pleiotropic effects of the agouti gene. Proc Natl Acad Sci USA 1995, 92:4721-4724.
19. Klebig ML, Wilkinson JE, Woychik RP: Molecular analysis of the mouse agouti gene and the role of dominant agouti-locus mutations in obesity and insulin resistance. In Molecular and Genetic Aspects of Obesity. Pennington Center Nutrition Series Volume 5 1st edition. Edited by: Bray GA, Ryan DH. Baton Rouge: Louisiana State University Press; 1996:120-160.
20. Michaud EJ, Mynatt RL, Miltenberger RJ, Klebig ML, Wilkinson JE, Zemel MB, Wilkison WO, Woychik RP: Role of the agouti gene in obesity. J Endocrinol 1997, 155:207-209.
21. Wolff GL, Roberts DW, Mountjoy KG: Physiological consequences of ectopic agouti gene expression: the yellow obese mouse syndrome. Physiol Genomics 1999,1:151-163.
22. Wolff GL: Regulation of yellow pigment formation in mice: a historical perspective. Pigment Cell Res 2003, 16:2-15.
23. y) is associated with the disruption of a novel RNA-binding protein. Genes Dev 1993, 7:1202-1213.
24. y mutation. Proc Natl Acad Sci USA 1994, 91:2562-2566.
25. y) mutation explained by deletion of a maternally expressed gene and the simultaneous production of agouti fusion RNAs. Development 1994, 120:1695-1708.
26. Duhl DM, Vrieling H, Miller KA, Wolff GL, Barsh GS: Neomorphic agouti mutations in obese yellow mice. Nat Genet 1994, 8:59-65.
27. Kiefer LL, Ittoop OR, Bunce K, Truesdale AT, Willard DH, Nichols JS, Blanchard SG, Mountjoy K, Chen WJ, Wilkison WO: Mutations in the carboxyl terminus of the agouti protein decrease agouti inhibition of ligand binding to the melanocortin receptors. Biochemistry 1997, 36:2084-2090.
28. Kim JH, Kiefer LL, Woychik RP, Wilkison WO, Truesdale A, Ittoop O, Willard D, Nichols J, Zemel MB: Agouti regulation of intracellular calcium: role of melanocortin receptors. Am J Physiol 1997, 272:E379-384.
29. Yang YK, Ollmann MM, Wilson BD, Dickinson C, Yamada T, Barsh GS, Gantz I: Effects of recombinant agouti-signaling protein on melanocortin action. Mol Endocrinol 1997, 11:274-280.
30. Mountjoy KG, Willard DH, Wilkison WO: Agouti antagonism of melanocortin-4 receptor: greater effect with desacetylalpha-melanocyte-stimulating hormone (MSH) than with alpha-MSH. Endocrinology 1999, 140:2167-2172.
31. Mountjoy KG, Kong PL, Taylor JA, Willard DH, Wilkison WO: Melanocortin receptor-mediated mobilization of intracellular free calcium in HEK293 cells. Physiol Genomics 2001, 5:11-19.
32. Huszar D, Lynch CA, Fairchild-Huntress V, Dunmore JH, Fang Q, Berkemeier LR, Gu W, Kesterson RA, Boston BA, Cone RD, Smith FJ, Campfield LA, Burn P, Lee F: Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 1997, 88: 31-141.
33. Yeo GS, Farooqi IS, Aminian S, Halsall DJ, Stanhope RG, O'Rahilly S: A frameshift mutation in MC4R associated with dominantly inherited human obesity. Nat Genet 1998, 20:111-112.
34. Vaisse C, Clement K, Guy-Grand B, Froguel P: A frameshift mutation in human MC4R is associated with a dominant form of obesity. Nat Genet 1998, 20:113-114.
35. Butler AA, Cone RD: The melanocortin receptors: lessons from knockout models. Neuropeptides 2002, 36:77-84.
36. Mynatt RL, Stevens JM: Agouti regulates adipocyte transcription factors. Am J Physiol Cell Physiol 2001, 280: 954-C961.
37. Jones BH, Kim JH, Zemel MB, Woychik RP, Michaud EJ, Wilkison WO, Moustaid N: Upregulation of adipocyte metabolism by agouti protein: possible paracrine actions in yellow mouse obesity. Am J Physiol 1996, 270:E192-E196.
38. y gene on mammarygland tumors, hepatomas, and normal growth in mice. J Natl Cancer Inst 1961, 26:969-983.
39. vy - A high hepatoma and high mammary tumor strain of mice. J Natl Cancer Inst 1968, 40:1161-1166.
40. Wolff GL: Differential growth of hepatoma-susceptible liver induced by genome × genome interaction. Cancer Res 1970, 30:1722-1725.
41. Wolff GL, Pitot HC: Variation of hepatic malic enzyme capacity with hepatoma susceptibility in mice of different genotypes. Cancer Res 1972, 32:1861-1863.
42. vy/A (C3H × VY) F-1 hybrid mice. Carcinogenesis 1986, 7: 895-1898.
43. vy) gene. Cancer Res 1986, 46:2241-2244.
44. Wolff GL, Roberts DW, Morrissey RL, Greenman DL, Allen RR, Campbell WL, Bergman H, Nesnow S, Frith CH: Tumorigenic responses to lindane in mice: potentiation by a dominant mutation. Carcinogenesis 1987, 8:1889-1897.
45. y) genes to enhance chemical induction of thymic lymphomas. Carcinogenesis 1988, 9:1673-1675.
46. y). J Natl Cancer Inst 1963, 31:189-195.
47. vy) agouti allele on skin tumorigenesis and humoral hypercalcemia in v-Ha-ras transgenic TG.AC mice. Carcinogenesis 1998, 19:1837-1845.
48. y ene of the mouse and susceptibility to induced pulmonary tumors. J Natl Cancer Inst 1942, 3:303-308.
49. y) gene of the mouse and susceptibility to spontaneous pulmonary tumors. J Natl Cancer Inst 1947, 7:463-465.
50. Heston WE, Vlahakis G: Elimination of the effect of the Ay gene on pulmonary tumors in mice by alteration of its effect on normal growth. J Natl Cancer Inst 1961, 27:1189-1196.
51. Little CC: The relationship of coat color to the spontaneous incidence of mammary tumors in mice. J Exper Med 1934, 59:229-250.
52. Vlahakis G, Heston WE, Smith GH: Strain C3H-A-vy-fB mice: ninety percent incidence of mammary tumors transmitted by either parent. Science 1970, 170:185-187.
53. Wolff GL, Medina D, Umholtz RL: Manifestation of hyperplastic alveolar nodules and mammary tumors in "viable yellow" and non-yellow mice. J Natl Cancer Inst 1979, 63:781-785.
54. vy/A) (Balb/c × VY) F1 hybrid mice. J Toxicol Environ Health 1982, 10:131-142.
55. Wolff GL, Gaylor DW, Frith CH, Suber RL: Controlled genetic variation in a subchronic toxicity assay: susceptibility to induction of bladder hyperplasia in mice by 2-acetylaminofluorene. J Toxicol Environ Health 1983, 12:255-265.
56. Pinkert CA, Ornitz DM, Brinster RL, Palmiter RD: An albumin enhancer located 10 kb upstream functions along with its promoter to direct efficient, liver-specific expression in transgenic mice. Genes Dev 1987, 1:268-276.
57. Klebig ML, Wilkinson JE, Geisler JG, Woychik RP: Ectopic expression of the agouti gene in transgenic mice causes obesity, features of type II diabetes, and yellow fur. Proc Natl Acad Sci USA 1995, 92:4728-4732.
58. Blanchard SG, Harris CO, Ittoop OR, Nichols JS, Parks DJ, Truesdale AT, Wilkison WO: Agouti antagonism of melanocortin binding and action in the B16F10 murine melanoma cell line. Biochemistry 1995, 34:10406-10411.
59. Willard DH, Bodnar W, Harris C, Kiefer L, Nichols JS, Blanchard S, Hoffman C, Moyer M, Burkhart W, Weiel J, Luther MA, Wilkison WO, Rocque WJ: Agouti structure and function: characterization of a potent alpha-melanocyte stimulating hormone receptor antagonist. Biochemistry 1995, 34:12341-12346.
60. Galbraith DB, Wolff GL: Aberrant regulation of the agouti pigment pattern in the viable yellow mouse. J Hered 1974, 65: 37-140.
61. Gantz I, Shimoto Y, Konda Y, Miwa H, Dickinson CJ, Yamada T: Molecular cloning, expression, and characterization of a fifth melanocortin receptor. Biochem Biophys Res Commun 1994, 200: 214-1220.
62. Labbe O, Desarnaud F, Eggerickx D, Vassart G, Parmentier M: Molecular cloning of a mouse melanocortin 5 receptor gene widely expressed in peripheral tissues. Biochemistry 1994, 33: 543-4549.
63. Fathi Z, Iben LG, Parker EM: Cloning, expression, and tissue distribution of a fifth melanocortin receptor subtype. Neurochem Res 1995, 20:107-113.
64. Mountjoy KG, Willard DH, Wilkison WO: Agouti antagonism of melanocortin-4 receptor: greater effect with desacetylalpha-melanocyte-stimulating hormone (MSH) than with alpha-MSH. Endocrinology 1999, 140:2167-2172.
65. Sambrook J, Fritsch EF, Maniatis T: Molecular Cloning: A Laboratory Manual Second edition. Plainview: Cold Spring Harbor Laboratory Press; 1989.
66. Overbeek PA, Aguilar-Cordova E, Hanten G, Schaffner DL, Patel P, Lebovitz RM, Lieberman MW: Coinjection strategy for visual identification of transgenic mice. Transgenic Res 1991, 1: 1-37.
67. Hogan B, Beddington R, Costantini F, Lacy E: Manipulating the Mouse Embryo: A Laboratory Manual Second edition. Plainview: Cold Spring Harbor Laboratory Press; 1994.
68. iapy) is correlated with methylation state and is influenced by parental lineage. Genes Dev 1994, 8:1463-1472.